Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month

Core Insights - Neuronetics, Inc. has launched the first National TMS Therapy Awareness Day on May 14, aimed at raising awareness about transcranial magnetic stimulation (TMS) as a non-drug treatment for major depressive disorder (MDD), anxiety, and OCD [1][2] Company Overview - Neuronetics is a commercial stage medical technology company focused on neurohealth therapies, with a mission to transform patients' lives [1] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for MDD and other mental health disorders across the United States [5][7] TMS Therapy Details - TMS therapy was first FDA-cleared in 2008 for treatment-resistant depression and has since gained widespread adoption as an evidence-backed treatment option [2] - NeuroStar is the leading TMS therapy in the U.S., with over 7.4 million treatments delivered and the largest clinical data set for TMS treatment of depression [7] - In 2024, NeuroStar received FDA clearance for use in adolescents aged 15-21, expanding access to younger patients [2][8] Awareness Campaign - The National TMS Awareness Day aims to provide hope to individuals who have not found relief through traditional antidepressants and to promote awareness of non-medication treatment options [2][6] - The campaign will include sharing patient and provider stories on social media to highlight the effectiveness of NeuroStar TMS therapy [6] Clinical Impact - The company will present new data at the 2025 American Psychiatric Association Annual Meeting, focusing on the efficacy of TMS protocols for treating MDD [4] - NeuroStar Advanced Therapy is cleared for various indications, including as an adjunct treatment for OCD and anxiety symptoms in patients with MDD [8]